Pyxis Oncology, Inc. (PYXS)
1.87
+0.19
(+11.31%)
USD |
NASDAQ |
Nov 20, 12:24
Pyxis Oncology Cash from Operations (Quarterly) : -16.29M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -16.29M |
| June 30, 2026 | -18.21M |
| March 31, 2026 | -26.00M |
| December 31, 2025 | -10.43M |
| September 30, 2025 | -13.28M |
| June 30, 2025 | -17.26M |
| March 31, 2025 | -22.54M |
| December 31, 2024 | -19.37M |
| September 30, 2024 | -14.65M |
| June 30, 2024 | -2.945M |
| March 31, 2024 | -20.71M |
| December 31, 2023 | -15.25M |
| Date | Value |
|---|---|
| September 30, 2023 | -17.58M |
| June 30, 2023 | -11.03M |
| March 31, 2023 | -26.84M |
| December 31, 2022 | -17.39M |
| September 30, 2022 | -20.56M |
| June 30, 2022 | -23.71M |
| March 31, 2022 | -27.68M |
| December 31, 2021 | -12.17M |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | -3.167M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Cypherpunk Technologies, Inc. | -2.902M |
| Cue Biopharma, Inc. | -10.08M |
| Yarrow Bioscience, Inc. | -89.96M |
| Faeth Therapeutics, Inc. | -13.00M |
| Indaptus Therapeutics, Inc. | -1.245M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -37.29M |
| Cash from Financing (Quarterly) | 38.58M |
| Free Cash Flow | -70.93M |
| Free Cash Flow Per Share (Quarterly) | -0.1951 |
| Free Cash Flow to Equity (Quarterly) | -15.86M |
| Free Cash Flow to Firm (Quarterly) | -16.29M |
| Free Cash Flow Yield | -45.42% |